Lv11
28 积分 2022-01-27 加入
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
1小时前
已完结
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
1小时前
已完结
Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer
1个月前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
2个月前
已完结
TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC)
2个月前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
6个月前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
6个月前
已完结
Advanced, recurrent, and persistent cervical cancer management: in the era of immunotherapy
6个月前
已完结
皖公网安备34019202002308
